Bamlanivimab cuts hospitalization, deaths in high-risk COVID outpatientsFewer high-risk outpatients with mild or moderate COVID-19 needed hospitalization or died within 28 days when given bamlanivimab soon after infection compared with their matched peers, finds an observational study yesterday in Open Forum Infectious Diseases.University of Pittsburgh researchers compared the outcomes of 232 COVID-19 outpatients given the monoclonal antibody (mAb) from Dec 9, 2020, to Mar 3, 2021, with those of 1,160 coronavirus patients of similar age and health status who didn't receive the drug.Bamlanivimab reduced the risk of hospitalization and death by 60% and was associated with a significantly lower risk-adjusted likelihood of hospitalization or